<DOC>
	<DOCNO>NCT00625768</DOCNO>
	<brief_summary>To determine tolerability , safety , end-organ toxicity maximum tolerate dose AS1409 single repeat dos .</brief_summary>
	<brief_title>Study AS1409 Patients With Either Metastatic Renal Cell Carcinoma Metastatic Malignant Melanoma</brief_title>
	<detailed_description>- To determine tolerability , safety , end-organ toxicity maximum tolerate dose ( MTD ) AS1409 single repeat dos . - To determine biological response AS1409 , include interferon-γ IP-10 circulating concentration . - To determine preliminary pharmacokinetics AS1409 . - To determine immunogenicity AS1409 - To explore anti-tumour activity AS1409 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Be 18 year old time give informed consent . Histologically confirm diagnosis renal cell carcinoma malignant melanoma . If renal cell carcinoma , clear cell chromophilic/papillary type , metastases site ( exclude patient single bony lesion ) . If malignant melanoma , unresectable Stage III disease Stage IV disease , metastases site ( exclude patient single bony lesion ) Patients clinically stable CNS metastasis may enter treat surgery radiation require steroid therapy . ECOG performance status 02 . Patients receive prior systemic treatment malignancy chemotherapeutic biological therapy may enter , provide treatment complete within 4 week study entry . Patients receive prior experimental therapy may enter , provide treatment complete within 12 week study entry . Have adequate bone marrow function evidence neutrophil &gt; 1.5 x109/L platelet &gt; 100 x109/L . Have adequate liver kidney function , show serum bilirubin ≤1.5x upper limit normal laboratory ; ALT AST ≤2x upper limit normal ; creatinine ≤1.5x upper limit normal . Have either evaluable measurable disease ( patient enter ascend dosage cohort ) measurable disease ( patient enter study MTD define ) . Patients fail ineligible standard first line therapy ( accordance individual institutional practice ) Patients follow exclude study : Patients poor medical risk nonmalignant systemic disease active infection . History clinically significant autoimmune predominantly Th1driven clinical disorder ( rheumatoid arthritis , psoriasis , chronic inflammatory bowel disease , example ) , exception autoimmune endocrinopathies treat replacement therapy . Diabetic retinopathy . Substantive surgery within 4 week prior study entry , expectation surgery study period . Malignancy renal cell carcinoma malignant melanoma within 5 year study entry , except nonmelanoma skin cancer cervical intraepithelial neoplasia treat definitively cancer patient diseasefree 5 year . Concurrent treatment systemic steroid immunosuppressive therapy . If female , pregnant breastfeeding ; Women child bear potential sexually active male , unless ( 1 ) patient ( female , patient 's partner , male ) surgically sterile ( 2 ) use adequate contraception ( define either IUD , oral depot contraceptive , barrier plus spermicide ) receive study treatment least 6 month termination treatment . Women must postmenopausal least 2 year consider nonchildbearing potential Any concurrent medical psychological condition would limit ability patient provide inform consent comply obligation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Antibody</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
	<keyword>efficacy</keyword>
	<keyword>metastatic renal cell carcinoma</keyword>
	<keyword>metastatic malignant melanoma</keyword>
</DOC>